Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;32(12):8726-8736.
doi: 10.1007/s00330-022-08873-6. Epub 2022 May 31.

Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer

Lan He  1 , Zhen-Hui Li  1   2 , Li-Xu Yan  3 , Xin Chen  4 , Sebastian Sanduleanu  5 , Wen-Zhao Zhong  6 , Phillippe Lambin  5   7 , Zhao-Xiang Ye  8 , Ying-Shi Sun  9 , Yu-Lin Liu  10 , Jin-Rong Qu  11 , Lin Wu  12 , Chang-Ling Tu  13 , Madeleine Scrivener  14 , Thierry Pieters  15 , Emmanuel Coche  16 , Qian Yang  10 , Mei Yang  17 , Chang-Hong Liang  1   18 , Yan-Qi Huang  19   20 , Zai-Yi Liu  21   22
Affiliations

Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer

Lan He et al. Eur Radiol. 2022 Dec.

Abstract

Objectives: To date, there are no data on the noninvasive surrogate of intratumoural immune status that could be prognostic of survival outcomes in non-small cell lung cancer (NSCLC). We aimed to develop and validate the immune ecosystem diversity index (iEDI), an imaging biomarker, to indicate the intratumoural immune status in NSCLC. We further investigated the clinical relevance of the biomarker for survival prediction.

Methods: In this retrospective study, two independent NSCLC cohorts (Resec1, n = 149; Resec2, n = 97) were included to develop and validate the iEDI to classify the intratumoural immune status. Paraffin-embedded resected specimens in Resec1 and Resec2 were stained by immunohistochemistry, and the density percentiles of CD3+, CD4+, and CD8+ T cells to all cells were quantified to estimate intratumoural immune status. Then, EDI features were extracted using preoperative computed tomography to develop an imaging biomarker, called iEDI, to determine the immune status. The prognostic value of iEDI was investigated on NSCLC patients receiving surgical resection (Resec1; Resec2; internal cohort Resec3, n = 419; external cohort Resec4, n = 96; and TCIA cohort Resec5, n = 55).

Results: iEDI successfully classified immune status in Resec1 (AUC 0.771, 95% confidence interval [CI] 0.759-0.783; and 0.770 through internal validation) and Resec2 (0.669, 0.647-0.691). Patients with higher iEDI-score had longer overall survival (OS) in Resec3 (unadjusted hazard ratio 0.335, 95%CI 0.206-0.546, p < 0.001), Resec4 (0.199, 0.040-1.000, p < 0.001), and TCIA (0.303, 0.098-0.944, p = 0.001).

Conclusions: iEDI is a non-invasive surrogate of intratumoural immune status and prognostic of OS for NSCLC patients receiving surgical resection.

Key points: • Decoding tumour immune microenvironment enables advanced biomarkers identification. • Immune ecosystem diversity index characterises intratumoural immune status noninvasively. • Immune ecosystem diversity index is prognostic for NSCLC patients.

Keywords: Computed tomography; Ecosystem; Immunohistochemistry; Non-small cell lung cancer; Prognosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ann Oncol. 2015 Feb;26(2):259-71 - PubMed
    1. Nat Rev Cancer. 2017 Oct;17(10):605-619 - PubMed
    1. Cancer Gene Ther. 2017 Feb;24(2):57-63 - PubMed
    1. CA Cancer J Clin. 2018 Jan;68(1):7-30 - PubMed
    1. Elife. 2017 Jul 21;6: - PubMed

LinkOut - more resources